Bugs As Drugs: The Budding Microbiome Modulator Pipeline
INFOGRAPHIC: The sheer number of micro-organisms in the human body and their functions makes the microbiome a ripe target for therapeutic intervention. While still rather early, data show the microbiome modulator pipeline has immense potential across a range of therapeutic areas, not just in gastrointestinal disease.
You may also be interested in...
While the atopic dermatitis market overall is crowded, the company sees a market opportunity for a drug that addresses both appearance and itching, as well as having favorable safety and ease of use.
Microbiome modulators, known mainly for development in infectious and gastrointestinal diseases, could prove an asset in oncology thanks to the work of biotechs.
The US biotech’s RSV treatment candidate has failed a Phase II study in low-risk patients leaving some experts skeptical of its hopes for potential improved performance in a high-risk setting.